# US 2021/0278400 A1 · Methods of assaying proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0278400 A1
- Document ID: US20210278400A1
- Status: Published application
- Kind: A1
- Application number: 17/153,877
- Filed: 2021-01-20
- Published: 2021-09-09
- Earliest claimed: 2016-12-01
- Assignees: Nautilus Biotechnology, Inc.
- Applicants: Nautilus Biotechnology, Inc.
- Inventors: Parag Mallick
- Web page: https://patentgrep.com/patent/US20210278400A1

## CPC

- G01N 33/54353: {with ligand attached to the carrier via a chemical coupling agent (coatings G01N33/54393)}
- G01N 33/6803: {General methods of protein analysis not limited to specific proteins or families of proteins}
- C12Q 1/6804: Nucleic acid analysis using immunogens (immunoassay G01N33/53)
- G01N 33/6878: {in epitope analysis}
- G01N 2458/10: Oligonucleotides as tagging agents for labelling antibodies
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Methods and systems for identifying a protein within a sample are provided herein. A panel of antibodies are acquired, none of which are specific for a single protein or family of proteins. Additionally, the binding properties of the antibodies in the panel are determined. Further, the protein is iteratively exposed to a panel of antibodies. Additionally, a set of antibodies which bind the protein are determined. The identity of the protein is determined using one or more deconvolution methods based on the known binding properties of the antibodies to match the set of antibodies to a sequence of a protein.

## Claims

### Claim at position 1

1-3. (canceled)

### Claim 4

A method for identifying a protein of a plurality of proteins, comprising:
(a) providing a plurality of proteins, wherein a protein of the plurality of proteins is immobilized at a position of an array;
(b) exposing the protein to a plurality of different affinity reagents, wherein affinity reagents of the plurality of different affinity reagents have a known degree of binding non-specificity for proteins of the plurality of different proteins;
(c) determining a binding pattern of the affinity reagents bound to the protein; and
(d) identifying the protein using the known degree of binding non-specificity of the affinity reagents and the binding pattern of the affinity reagents bound to the protein.

### Claim 5 (depends on 4)

The method of claim 4, wherein said position precludes binding of another protein.

### Claim 6 (depends on 4)

The method of claim 4, further comprising treating the plurality of proteins to retain posttranslational protein modifications.

### Claim 7 (depends on 4)

The method of claim 4, further comprising treating the plurality of proteins to remove posttranslational protein modifications.

### Claim 8 (depends on 6)

The method of claim 6, wherein said posttranslational protein modifications comprise phosphorylation, glycosylation, methylation, ubiquitination, myristoylation, palmitoylation, isoprenylation, prenylation, farnesylation, geranylgeranylation, glypiation, lipoylation, flavin moiety attachment, phosphopantetheinylation, or retinylidene Schiff base formation.

### Claim 9 (depends on 4)

The method of claim 4, further comprising coupling the plurality of proteins to the array via an intermediate substance.

### Claim 10 (depends on 9)

The method of claim 9, wherein the intermediate substance comprises a nucleic acid.

### Claim 11 (depends on 10)

The method of claim 10, wherein the nucleic acid comprises a nucleic acid nanoball.

### Claim 12 (depends on 11)

The method of claim 11, wherein the nucleic acid nanoball comprises a DNA nanoball.

### Claim 13 (depends on 9)

The method of claim 9, wherein the intermediate substance comprises biotin.

### Claim 14 (depends on 9)

The method of claim 9, wherein the intermediate substance comprises a bead.

### Claim 15 (depends on 4)

The method of claim 4, further comprising adding a functional group to a surface of the array.

### Claim 16 (depends on 15)

The method of claim 15, wherein the functional group comprises a maleic moiety, a succinic moiety, an amino group, a thiol group, an acrylate group, a N-Hydroxysuccinimide (NHS) functional groups, an acrylate, an epoxy, or a PEG molecule.

### Claim 17 (depends on 4)

The method of claim 4, wherein the plurality of different affinity reagents comprises monoclonal antibodies.

### Claim 18 (depends on 4)

The method of claim 4, wherein the plurality of different affinity reagents comprises antibody fragments.

### Claim 19 (depends on 4)

The method of claim 4, wherein the plurality of different affinity reagents comprises aptamers.

### Claim 20 (depends on 4)

The method of claim 4, wherein affinity reagents of the plurality of different affinity reagents bind to an epitope flanked by different amino acid sequences.

### Claim 21 (depends on 4)

The method of claim 4, wherein affinity reagents of the plurality of different affinity reagents are linked to identifiable tags.

### Claim 22 (depends on 21)

The method of claim 21, wherein the identifiable tags comprise a plurality of fluorophores.

### Claim 23 (depends on 22)

The method of claim 22, wherein the plurality of fluorophores comprises different patterns of excitation or emission.

### Claim 24 (depends on 21)

The method of claim 21, wherein (c) further comprises observing a signal of the identifiable tags linked to the plurality of different affinity reagents bound to the protein.

### Claim 25 (depends on 4)

The method of claim 4, wherein the plurality of proteins is obtained or derived from a blood sample from a pregnant subject.

### Claim 26 (depends on 25)

The method of claim 25, wherein the plurality of proteins is obtained or derived from circulating fetal cells in the blood sample.

### Claim 27 (depends on 4)

The method of claim 4, wherein (b) comprises iteratively exposing the protein to the plurality of different affinity reagents.

### Claim 28 (depends on 4)

The method of claim 4, wherein at least one of the plurality of different affinity reagents has a binding affinity for different proteins, and wherein at least one of the plurality of different proteins has a binding affinity for different affinity reagents.
